RELA and B-cell chronic lymphocytic leukemia: For example, MLN4924 treatment induced the accumulation of pIκBα, preventing nuclear translocation of RelA/p65, resulting in inhibition of the activation, proliferation, and release of IL-2 by T cells, eventually leading to reduced Treg genesis and a shift to the TH1 phenotype with increased production of IFN-γ production in human CLL T cells [98].